Brief: Candel Therapeutics Announces Oral Presentation Of Updated Data From Its Phase 1 Clinical Trial Of CAN-3110
18/11/2022 13:08
Nov 18 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS ANNOUNCES ORAL PRESENTATION OF UPDATED
DATA
FROM ITS PHASE 1 CLINICAL TRIAL OF CAN-3110 IN 41 PATIENTS WITH
RECURRENT HIGH-GRADE GLIOMA AT THE SOCIETY FOR NEURO-ONCOLOGY
27TH ANNUAL MEETING
* CANDEL THERAPEUTICS INC - NO DOSE-LIMITING TOXICITIES
OBSERVED
IN 41 PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA (RHGG)
* CANDEL THERAPEUTICS INC - MEDIAN OVERALL SURVIVAL WAS 11.6
MONTHS AFTER A SINGLE INJECTION OF CAN-3110 IN PATIENTS WITH
RHGG
Source text for Eikon: ID:nGNXgwGN2
Further company coverage: CADL.O
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec